Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells 1,786 Shares of Stock

March 7, 2026 by InsiderTrades.com

Key Points

CEO Claire Mazumdar sold a total of 8,234 Bicara shares across March 4–6 at roughly $18.74 per share (~$154k), with the March 5 sale alone reported as a 0.52% reduction leaving her with 339,392 shares valued at about $6.36M.
Several other executives also executed sizable sales (CFO Ivan Hyep ~16,518 shares, COO Ryan Cohlhepp ~17,392 shares, and insider David Raben ~16,500 shares), signaling material insider liquidity-taking that could weigh on near-term sentiment.
Despite the insider selling, institutional buyers have been adding positions and analysts remain largely positive — the consensus target is about $28.33 while BCAX trades near $18.47 with a market cap around $1.01B.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $18.74, for a total transaction of $33,469.64. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company's stock, valued at $6,360,206.08. The trade was a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Claire Mazumdar also recently made the following trade(s):

On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total value of $49,278.63.

Bicara Therapeutics Stock Performance

NASDAQ BCAX traded down $0.03 during trading hours on Friday, hitting $18.47. 471,766 shares of the company's stock were exchanged, compared to its average volume of 541,313. The business's 50 day moving average is $16.47 and its 200-day moving average is $15.75. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $19.71. The firm has a market capitalization of $1.01 billion, a P/E ratio of -8.25 and a beta of -0.78.

Key Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Institutional Trading of Bicara Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its position in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after buying an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock valued at $44,000 after buying an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Bicara Therapeutics during the 4th quarter worth approximately $45,000. Finally, Larson Financial Group LLC boosted its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after acquiring an additional 3,595 shares during the period.

Analyst Ratings Changes

Several equities analysts recently commented on BCAX shares. HC Wainwright reaffirmed a "buy" rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Citigroup began coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set an "outperform" rating for the company. Wells Fargo & Company lifted their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Tuesday, November 11th. Mizuho upgraded Bicara Therapeutics to a "hold" rating in a research note on Thursday, December 18th. Finally, UBS Group restated a "buy" rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $28.33.

Read Our Latest Stock Report on Bicara Therapeutics

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.